67亿美元！辉瑞拟收购ARENA PHARMACEUTICALS

辉瑞公司（纽约证券交易所代码：PFE）和 Arena Pharmaceuticals 公司（纳斯达克代码：ARNA）今天刚刚宣布，两家公司已达成最终协议，辉瑞将收购Arena，一家开发治疗多种免疫炎症性疾病的创新潜在疗法的临床阶段公司 。根据协议条款，辉瑞将以每股100美元的全现金交易方式收购Arena的所有流通股，总股本价值约为 67亿美元。两家公司的董事会一致通过了此项交易。

Arena 的产品组合包括胃肠病学、皮肤病学和心脏病学领域的多种有前途的开发阶段候选药物，包括 etrasimod，一种口服选择性 1-磷酸鞘氨醇 (S1P) 受体调节剂，目前正在开发阶段，针对一系列免疫炎症疾病，包括胃肠道和皮肤病 疾病。

辉瑞炎症和免疫学全球总裁兼总经理Mike Gladstone表示：“对Arena的潜在收购补充了我们在炎症和免疫学方面的能力和专业知识，这些是辉瑞的创新引擎，正在为需要更有效治疗选择的衰弱性免疫炎症疾病患者开发潜在疗法。利用辉瑞领先的研究和全球开发能力，我们计划加速针对免疫炎症性疾病患者的etrasimod的临床开发。”

了解详情，请阅读辉瑞公司的新闻稿。仅供个人谨慎参考。

PFIZER TO ACQUIRE ARENA PHARMACEUTICALS

December 13, 2021

Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases

Expands innovative pipeline potentially enhancing growth through 2025 and beyond

Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion

Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives

NEW YORK & PARK CITY, Utah--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion. The boards of directors of both companies have unanimously approved the transaction.

Arena’s portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases.

“The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options,” said Mike Gladstone, Global President & General Manager, Pfizer Inflammation and Immunology. “Utilizing Pfizer’s leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases.”

Arena has built a robust development program for etrasimod, including two Phase 3 studies in ulcerative colitis (UC), a Phase 2/3 program in Crohn’s Disease, a planned Phase 3 program in atopic dermatitis, and ongoing Phase 2 studies in eosinophilic esophagitis and alopecia areata.

In UC, the randomized, placebo-controlled, dose-ranging, Phase 2 study (OASIS) evaluated the efficacy and safety of etrasimod in moderate to severe UC patients over 12 weeks versus placebo. In the study, most patients who achieved clinical response, clinical remission, or endoscopic improvement at week 12 experienced sustained or improved effects up to week 46 with etrasimod 2 mg in the open-label extension. Etrasimod also demonstrated a favorable benefit/risk profile, consistent with safety findings reported in the double-blind portion of OASIS. The findings are encouraging as there remains significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response, or intolerance to conventional or advanced therapies. The OASIS trial supported the advancement of the ELEVATE UC 52 and UC 12 trials, which are currently fully enrolled, and for which data are expected in 2022.

In addition, Arena’s pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. Temanogrel is currently in Phase 2 for the treatment of microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis. APD418 is currently in Phase 2 for acute heart failure.

“We’re delighted to announce Pfizer’s proposed acquisition of Arena, recognizing Arena’s potentially best in class S1P molecule and our contribution to addressing unmet needs in immune-mediated inflammatory diseases,” said Amit D. Munshi, President and Chief Executive Officer of Arena. “Pfizer’s capabilities will accelerate our mission to deliver our important medicines to patients. We believe this transaction represents the best next step for both patients and shareholders.”

Pfizer expects to finance the transaction with existing cash on hand.

Under the terms of the merger agreement, Pfizer will acquire all of the outstanding shares of Arena common stock for $100 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena’s stockholders.

Pfizer’s financial advisors for the transaction are BofA Securities and Centerview Partners LLC, with Ropes & Gray and Arnold & Porter Kaye Scholer LLP acting as its legal advisors. Guggenheim Securities, LLC and Evercore Group LLC served as Arena’s financial advisors, while Cooley LLP served as its legal advisor.

版权声明/免责声明

本文为编译文章，仅代表作者观点，版权归作者。

仅供感兴趣的个人谨慎参考，非商用，非医用、非投资用。

欢迎朋友们批评指正！衷心感谢！

文中图片、视频为授权正版作品，或来自微信公共图片库，或取自网络

根据CC0协议使用，版权归拥有者。

任何问题，请与我们联系（电话：[phone]。微信：27674131。邮箱：[e-mail]）。衷心感谢！

推荐阅读

点击这里，与～20万同药们喜相逢！